Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

Sponsor
LG Chem
Study ID
NCT05105698
Phase
PHASE1
Status
Unknown

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

A Randomized, Open-label, Single-dose, Two-way Crossover Study to Investigate Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated Tablet under Fed and Fasting Conditions in Healthy Volunteers

Key Dates

Start date
Jan 1, 2022
Status verified
Oct 2021
Primary completion
Feb 28, 2022
Completion
Sep 30, 2022

Study Design

Enrollment
28 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: fasting conditions
    A: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once without food (fasting conditions)
  • Experimental: fed conditions
    B: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once with food (fed conditions)

Primary Outcome Measure

Peak Plasma Concentration (Cmax) [ Time Frame: Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00 ]

Central Contacts

Related Studies